Related Experiment Video
Updated: May 29, 2026
08:35
Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
Published on: May 26, 2022
Hepatorenal syndrome: do the vasoconstrictors work?
1Division of Gastroenterology, Department of Medicine, 9N/983, Toronto General Hospital, University of Toronto, 200 Elizabeth Street, Toronto, Ontario M5G2C4, Canada.
Gastroenterology Clinics of North America
|September 7, 2011
Summary
Hepatorenal syndrome (HRS) treatments, including vasoconstrictors and TIPS, show promise. Liver transplantation is crucial for HRS patients, improving survival, especially when HRS is reversed before the procedure.
Area of Science:
- Gastroenterology and Hepatology
- Nephrology
- Transplantation Medicine
Background:
- Hepatorenal syndrome (HRS) is a severe complication of advanced cirrhosis.
- Hemodynamic abnormalities in cirrhosis contribute to HRS development.
- Current treatments for HRS have limited efficacy in a significant portion of patients.
Purpose of the Study:
- To review current and emerging treatment strategies for hepatorenal syndrome (HRS).
- To evaluate the role of vasoconstrictors, TIPS, and liver transplantation in managing HRS.
- To provide guidance on patient selection for combined liver-kidney transplantation.
Main Methods:
- Review of existing literature on hepatorenal syndrome treatments.
- Analysis of data regarding the efficacy of vasoconstrictors and TIPS.
- Assessment of outcomes associated with liver transplantation in HRS patients.
Main Results:
- Vasoconstrictors are effective in approximately 40% of HRS patients by correcting hemodynamic abnormalities.
- Combination therapy with vasoconstrictors and Transjugular Intrahepatic Portosystemic Shunting (TIPS) may offer superior outcomes.
- Reversing HRS prior to liver transplantation is linked to improved long-term survival.
Conclusions:
- Early assessment for liver transplantation is recommended for all HRS patients.
- Combined liver-kidney transplantation is indicated for irreversible kidney injury.
- Sequential liver transplantation followed by kidney transplant consideration is a viable strategy for other cases.
Related Concept Videos
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:22Heart Failure Drugs: Diuretics
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
01:23Antihypertensive Drugs: Vasodilators
Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
01:25Antihypertensive Drugs: Direct Renin Inhibitors
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
01:11Renal Failure: Dose Adjustments
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...